Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$60.48 +0.2%	$61.42	$43.70 ▼ $86.53	$1.93B	-1.44	46,044 shs	83,537 shs
GMTX Gemini Therapeutics	$51.61 +3.0%	$46.96	$1.16 ▼ $14.10	$2.24B	-0.12	189,291 shs	413,983 shs
NAMS NewAmsterdam Pharma	$17.96 -1.3%	$18.51	$14.06 ▼ $27.29	$2.02B	-0.03	696,648 shs	1.01 million shs
SBTX Silverback Therapeutics	$15.80 -0.7%	$14.33	$2.80 ▼ $8.97	$569.72M	0.6	337,931 shs	1.34 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	+1.56%	-0.85%	-9.65%	+24.70%
GMTX Gemini Therapeutics	0.00%	-3.91%	+7.43%	-1.21%	+16.82%
NAMS NewAmsterdam Pharma	0.00%	-11.13%	+1.99%	-25.17%	-0.33%
SBTX Silverback Therapeutics	0.00%	+2.66%	+8.82%	+27.83%	+93.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.6546 of 5 stars	3.5	3.0	0.0	0.0	3.2	0.8	0.6
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	3.0046 of 5 stars	3.5	2.0	0.0	0.0	2.6	5.0	0.0
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	59.83% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	138.80% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SBTX, GMTX, NAMS, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
4/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
3/26/2025	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.72 per share	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
NAMS NewAmsterdam Pharma	$45.56M	44.26	N/A	N/A	$8.20 per share	2.19
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$36.14M	-$1.36	N/A	N/A	N/A	N/A	-32.07%	-30.91%	8/8/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A

Latest SBTX, GMTX, NAMS, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	24.31	24.31
GMTX Gemini Therapeutics	N/A	71.49	71.49
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
SBTX Silverback Therapeutics	N/A	67.87	67.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
GMTX Gemini Therapeutics	75.42%
NAMS NewAmsterdam Pharma	89.89%
SBTX Silverback Therapeutics	74.89%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
GMTX Gemini Therapeutics	12.90%
NAMS NewAmsterdam Pharma	20.84%
SBTX Silverback Therapeutics	34.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable

SBTX, GMTX, NAMS, and BLTE Headlines

Recent News About These Companies

Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 6.8% - Here's Why

June 3, 2025 | marketbeat.com

Meet the Silverback, the Leader of the Troop

October 17, 2024 | pbs.org

10 Fun Facts About Mountain Gorillas

September 18, 2024 | nationalgeographic.com

CapstanTx secures $165 million to deliver precise in vivo cell engineering

July 28, 2024 | pharmaphorum.com

ARS Pharmaceuticals Inc (SPRY)

May 11, 2023 | uk.investing.com

Wild Isles

March 12, 2023 | wwf.org.uk

A look back at RNA Therapeutics – day one

February 24, 2023 | pharmaphorum.com

SPRY ARS Pharmaceuticals, Inc.

January 24, 2023 | seekingalpha.com

ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger

November 22, 2022 | 247wallst.com

Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics

November 18, 2022 | nasdaq.com

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

November 10, 2022 | finance.yahoo.com

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

November 8, 2022 | finance.yahoo.com

Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions

October 28, 2022 | markets.businessinsider.com

FDA accepts ARS Pharma’s NDA for Neffy

October 24, 2022 | thepharmaletter.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI

October 23, 2022 | kentuckytoday.com

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

October 21, 2022 | finance.yahoo.com

Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?

October 19, 2022 | aaii.com

SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN

October 12, 2022 | bakersfield.com

INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT

September 17, 2022 | markets.businessinsider.com

SBTX Silverback Therapeutics, Inc.

September 15, 2022 | seekingalpha.com

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT

September 6, 2022 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX, GMTX, NAMS, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

$60.48 +0.12 (+0.20%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$60.50 +0.02 (+0.02%)

As of 06/20/2025 04:04 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Gemini Therapeutics NASDAQ:GMTX

$51.61 +1.52 (+3.03%)

As of 06/20/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$17.96 -0.24 (-1.32%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$18.15 +0.19 (+1.06%)

As of 07:14 AM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Silverback Therapeutics NASDAQ:SBTX

$15.80 -0.11 (-0.69%)

As of 06/20/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time